Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Recent progress in the development of anticancer agents.

Sándor Eckhardt1

  • 1National Institute of Oncology, 1122 Budapest Ráth Gy. u. 7/9 Hungary. eckhardt@oncol.hu

Current Medicinal Chemistry. Anti-Cancer Agents
|April 8, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Systemic therapy of breast cancer: practice guideline].

Magyar onkologia·2016
Same author

Inflammatory breast cancer-comparing the effectivity of preoperative docetaxel-epirubicine protocol to conventional antracycline-containing chemotherapy to achieve clinical benefit and complete pathological response.

Pathology oncology research : POR·2010
Same author

[Pharmaceutical therapy of breast cancer].

Magyar onkologia·2010
Same author

Epidermal growth factor receptor (EGFR) high gene copy number and activating mutations in lung adenocarcinomas are not consistently accompanied by positivity for EGFR protein by standard immunohistochemistry.

The Journal of molecular diagnostics : JMD·2008
Same author

Molecular targeted therapy: a strategy of disillusions or optimism?

The Journal of laboratory and clinical medicine·2006
Same author

[Clinical studies with imatinib in 2004].

Orvosi hetilap·2005
Same journal

Selenium derivatives as cancer preventive agents.

Current medicinal chemistry. Anti-cancer agents·2005
Same journal

Lycopene: a review of its potential as an anticancer agent.

Current medicinal chemistry. Anti-cancer agents·2005
Same journal

Sulfo-quinovosyl-acyl-glycerol (SQAG), a eukaryotic DNA polymerase inhibitor and anti-cancer agent.

Current medicinal chemistry. Anti-cancer agents·2005
Same journal

Current drug therapy for prostate cancer: an overview.

Current medicinal chemistry. Anti-cancer agents·2005
Same journal

Lanthanides as anticancer agents.

Current medicinal chemistry. Anti-cancer agents·2005
Same journal

Inhibition of PI3K/Akt signaling: an emerging paradigm for targeted cancer therapy.

Current medicinal chemistry. Anti-cancer agents·2005
See all related articles

Cancer chemotherapy has evolved from early cytotoxic agents to novel targeted therapies. Research now focuses on less toxic compounds and new strategies like chemoprevention and anti-metastatic treatments for improved cancer management.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Chemotherapy's history began with N-mustard, leading to alkylating agents, antimetabolites, and antimitotics.
  • Significant toxicity and chemoresistance of early drugs highlighted the need for safer, broader-spectrum anticancer agents.
  • Advances in molecular biology revealed new targets, enabling the development of novel chemotherapeutic strategies.

Purpose of the Study:

  • To review existing and investigational anticancer drugs.
  • To explore emerging therapeutic concepts in cancer treatment.
  • To address the limitations of traditional chemotherapy.

Main Methods:

  • Review of historical and current chemotherapy agents.
  • Analysis of molecular targets in cancer metabolism and cell signaling.

Related Experiment Videos

  • Examination of novel therapeutic approaches including chemoprevention, anti-metastatic, anti-angiogenic, and anti-telomerase therapies.

    • Main Results:

    • Identification of key molecular targets for drug development, including signal transduction pathways and cell cycle regulators.
    • Emergence of new therapeutic strategies such as chemoprevention, neoadjuvant anti-metastatic therapy, anti-angiogenic therapy, and anti-telomerase molecules.
    • Recognition of the need to re-evaluate current and investigational drugs in light of these advancements.

    Conclusions:

    • Modern cancer research leverages molecular biology to identify novel drug targets and develop less toxic, more effective treatments.
    • Innovative therapeutic strategies are expanding the scope of cancer management beyond traditional chemotherapy.
    • A comprehensive review of existing and investigational agents is crucial for advancing cancer therapy.